October 2, 2016
Cardiovascular disease (CVD) is the leading cause of death in the world, yearly accounting for over 17 million deaths. To improve the life-expectancy of CVD patients, a multi-partner consortium has been brought together funded by the European Union to take on the challenge to advance the drug development for the treatment of cardiovascular diseases.
CVD affects the heart and surrounding blood vessels and can take many forms, such as high blood pressure, coronary artery disease, heart disease and stroke. Progression is slow without clear symptoms warning for this life-threatening disease. Although the introduction of statins has reduced the morbidity and mortality of atherosclerosis by 30%, still a major residual cardiovascular risk remains, which necessitates the development of new medicines. The goal of the EU project CarTarDis (Cardiovascular Target Discovery) is to advance the development of CVD medicines by discovery and validation of novel therapeutics targets to CVD.
Cartardis partner Imabiotech presented poster ‘Multimodal Analysis and Mass Spectrometry Imaging of Atherosclerotic Plaque Tissue’ at the 2016 ASMS meeting
August 24, 2016
A systematic evaluation of the cellular innate immune response during the process of human atherosclerosis, paper supported by CarTarDis published by AHA
August 16, 2016
June 3, 2016
PolyGene presented poster ‘Novel Glucocorticoid-based Gene Regulation System’ at Transgenic Technology Meeting
April 6, 2016
September 28, 2015
August 11, 2015
June 24, 2015
March 2, 2015
September 29, 2014